BioCryst Pharmaceuticals (BCRX) to Release Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is projected to release its earnings data before the market opens on Monday, February 24th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.06) per share and revenue of $131.10 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $9.05 on Monday. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.11. The stock has a market capitalization of $1.87 billion, a PE ratio of -14.84 and a beta of 1.75. The business’s 50-day simple moving average is $7.86 and its 200-day simple moving average is $7.77.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BCRX shares. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, Barclays lifted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.